The global market for glial cell line-derived neurotrophic factors is expected to expand at a rapid pace (2024-2031). The rising incidence of Parkinson’s disease (PD) throughout the world is one of the primary reasons driving the market’s rise. According to the Parkinson Foundation, almost one million persons in the US suffer with Parkinson’s disease, with the number expected to increase to 1.2 million by 2030. Furthermore, approximately 60,000 Americans are diagnosed with Parkinson’s disease each year, and the disease affects over 10 million people globally. Parkinson’s disease increases with age; nevertheless, only around 4% of those diagnosed with Parkinson’s disease are under the age of 50. Men are 1.5 times more likely than women to get Parkinson’s disease. As a result of the increasing prevalence of this disease, the need for glial cell line derived neurotrophic factors for therapy is increasing, propelling the global glial cell line derived neurotrophic factor market ahead. The GDNF gene encodes a protein called glial cell-derived neurotrophic factor. GDNF is a tiny protein that aids in the survival of several neuronal types by binding to GFR receptors, notably GFR1.
Get Free Sample link @ https://www.omrglobal.com/request-sample/glial-cell-line-derived-neurotrophic-factor-market
Furthermore, ongoing clinical trials for the treatment of Parkinson’s disease provide a considerable prospect for market growth. For instance, on January 3, 2020, National Cheng-Kung University Hospital began clinical research examining the efficacy of Hericium Erinaceus Mycelium on Parkinson’s disease non-motor symptoms (NMS). The goal of this experiment is to conduct a randomised, controlled trial to see how Hericium Erinaceus mycelium, which is high in Erinacine A, affects Parkinson’s disease NMS.
Full report of Glial Cell Line Derived Neurotrophic Factor Market available @ https://www.omrglobal.com/industry-reports/glial-cell-line-derived-neurotrophic-factor-market
Market Coverage
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- GlaxoSmithKline plc, Treeway BV, and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Glial Cell Line Derived Neurotrophic Factor Market Report Segment.
By Type
- GSK-812
- LAUR-301
- TW-002
- AMT-090
By Application
- Amyotrophic Lateral Sclerosis
- Brain Ischemia
- Parkinson’s disease
- Retinal Degeneration
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/glial-cell-line-derived-neurotrophic-factor-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
